News & Updates

Participants with early-onset obesity in the SURMOUNT clinical trials show a mixed profile of metabolic health at baseline despite a relatively young biological age. They exhibit concerning features, such as higher waist circumference and fasting insulin, as well as favourable features, including lower systolic blood pressure (SBP) and HbA1c compared with the late-onset group.

Subcutaneous (SC) semaglutide 2.4 mg QW is recently granted accelerated approval by the US FDA for treatment of metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.